Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

OTC Coverage Under Rx Plans May Help Restrain Drug Costs - Ford Exec

  • News

Executive Summary

Expanding drug coverage to include OTCs may merit consideration as a means to restrain growth in pharmacy budgets, Ford Healthcare Management Director Woodrow Myers, MD, suggested.

You may also be interested in...



General Motors Meets With Pharma Companies To Discuss Rx Pricing, DTC

General Motors is meeting with pharmaceutical manufacturers to discuss drug cost issues.

General Motors Meets With Pharma Companies To Discuss Rx Pricing, DTC

General Motors is meeting with pharmaceutical manufacturers to discuss drug cost issues.

Ford's $13 Mil. Annual Prilosec Spend Partly Due To DTC Ads, Exec Says

Over-prescribing of AstraZeneca's proton pump inhibitor Prilosec to Ford Motor Company health beneficiaries can be partly attributed to direct-to-consumer advertising, Ford Motor Company Health Care Management Director Woodrow Myers, MD, maintained at a health care conference sponsored by the Wall Street Journal May 5 in Washington, D.C.

Table

View full table

Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS036071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By